Gastroesophageal Reflux Disease (GERD) Therapeutics Market Overview, Value Chain Analysis and Regional Landscape, 2025
The global Gastroesophageal Reflux Disease (GERD) therapeutics market is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%.
(firmenpresse) - The global Gastroesophageal Reflux Disease (GERD) Therapeutics Market research report provides complete insights on industry scope, global trends, regional estimates, key application, competitive landscape and financial performance of prominent players. It also offers ready, data-driven answers to several industry-level questions. This study enables numerous opportunities for the market players to invest in research and development.
Market Overview:
The global Gastroesophageal Reflux Disease (GERD) therapeutics market size was valued at USD 5.66 billion in 2016 and is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR of -2.9%. Expiration of patented blockbuster drugs, which are indicated for the management of disorders of acid reflux is major restraining factors for this market.
Upon loss of patent protection of formerly leading branded drugs, generic molecules with low-price can ingest the sales of the branded ones up to 90%. Rising number of companies being exposed to price scrutiny associated with shift in the focus of government on the promotion of consumer convenience will stimulate further reduction of drug prices. Although market turnover is affected by the expiration of major patents and the demand of drugs used to reduce acid, due to the increasing prevalence of heartburn, is anticipated to increase in the upcoming years.
Key Players:
Takeda Pharmaceutical Co., Ltd.
AstraZeneca PLC
Eisai Co., Ltd.
GlaxoSmithKline PLC.
Johnson & Johnson Services, Inc.
Daewoong Pharmaceutical Co., Ltd
Ironwood Pharmaceuticals, Inc.
Request free sample to get a complete analysis of top-performing companies (at) https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market/request-sample
Nevertheless, the advent of devices which are minimally invasive to address anatomical defects are gaining popularity coupled with supportive evidence from clinical data for performing various procedures including trans oral fundoplication, which helps in preventing reflux of non-acid and acid contents. The adoption of these devices have been further reinforced in the U.S. in 2016 with the advent of a CPT code (43210) which helps in facilitating reimbursement process.
Application Outlook:
Antacids
H2 Receptor Blockers
Proton Pump Inhibitors (PPIs)
Pro-kinetic agents
Regional Insights:
In 2016, the largest region was found to be North America in terms of share for GERD market. Every year, GERD symptoms are experienced by more than 80 million people in the U.S., of which, approximately 25 million patients suffer from acid reflux and heartburn daily and approximately 60 million patients monthly.
Moreover, outpatient clinic visits for GERD disorder in the U.S. has been increased in the past few years because of the more prone geriatric population to develop acid reflux and heartburn. On the contrary, the Asia Pacific is estimated to witness the fastest growth rate. The increasing geriatric population and dietary and lifestyle risk factors such as diet with high fat and obesity, is anticipated to drive the growth. In developing countries, the inclination towards self-medication is quickly increasing because of the affordability and availability of OTC antacids as in China and India.
Browse Related Category Research Reports (at) https://blog.naver.com/tomclark
Themen in dieser Pressemitteilung:
healthcare
gastroesophageal-reflux-disease-gerd-therapeutics-market
gastroesophageal-reflux-disease-gerd-therapeutics-market-news
global-gastroesophageal-reflux-disease-gerd-therapeutics-industry-size
Unternehmensinformation / Kurzprofil:
Datum: 25.09.2020 - 12:41 Uhr
Sprache: Deutsch
News-ID 620071
Anzahl Zeichen: 3850
contact information:
Contact person: Tom Clark
Town:
Felton
Phone: 4086102300
Kategorie:
Healthcare
Typ of Press Release: Financial
type of sending: don't
Date of sending: 25.09.2020
Diese Pressemitteilung wurde bisher 367 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Gastroesophageal Reflux Disease (GERD) Therapeutics Market Overview, Value Chain Analysis and Regional Landscape, 2025"
steht unter der journalistisch-redaktionellen Verantwortung von
Million Insights (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
